SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Apr 3

PMID 33802729

Citations 28

Authors

Szu-Wei Huang

Sheng-Fan Wang

Affiliations

Soon will be listed here.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved to display particular patterns of genetic diversity in the genome across geographical regions. These variations in the virus and genetic variation in human populations can determine virus transmissibility and coronavirus disease 2019 (COVID-19) severity. Genetic variations and immune differences in human populations could be the driving forces in viral evolution. Recently emerged SARS-CoV-2 variants show several mutations at the receptor binding domain in the spike (S) glycoprotein and contribute to immune escape and enhanced binding with angiotensin 1-converting enzyme 2 (ACE2). Since ACE2 and transmembrane protease serine 2 (TMPRSS2) play important roles in SARS-CoV-2 entry into the cell, genetic variation in these host entry-related proteins may be a driving force for positive selection in the SARS-CoV-2 S glycoprotein. Dendritic or liver/lymph cell-specific intercellular adhesion molecule (ICAM)-3-grabbing non-integrin is also known to play vital roles in several pathogens. Genetic variations of these host proteins may affect the susceptibility to SARS-CoV-2. This review summarizes the latest research to describe the impacts of genetic variation in the viral S glycoprotein and critical host proteins and aims to provide better insights for understanding transmission and pathogenesis and more broadly for developing vaccine/antiviral drugs and precision medicine strategies, especially for high risk populations with genetic risk variants.

Citing Articles

Impact of African-Specific ACE2 Polymorphisms on Omicron BA.4/5 RBD Binding and Allosteric Communication Within the ACE2-RBD Protein Complex.

Barozi V, Tastan Bishop O Int J Mol Sci. 2025; 26(3).

PMID: 39941135 PMC: 11818624. DOI: 10.3390/ijms26031367.

Impact of Prolonged SARS-CoV-2 Viral Shedding on COVID-19 Disease Outcome and Viral Dynamics.

Sanyaolu A, Marinkovic A, Prakash S, Balendra V, Hamdy K, Haider N Indian J Microbiol. 2024; 64(4):1416-1424.

PMID: 39678987 PMC: 11645332. DOI: 10.1007/s12088-024-01238-1.

Identification and evaluation of candidate COVID-19 critical genes and medicinal drugs related to plasma cells.

Liu Z, Petinrin O, Chen N, Toseef M, Liu F, Zhu Z BMC Infect Dis. 2024; 24(1):1099.

PMID: 39363208 PMC: 11451256. DOI: 10.1186/s12879-024-10000-3.

Silver and Carbon Nanomaterials/Nanocomplexes as Safe and Effective ACE2-S Binding Blockers on Human Skin Cell Lines.

Hotowy A, Strojny-Cieslak B, Ostrowska A, Zielinska-Gorska M, Kutwin M, Wierzbicki M Molecules. 2024; 29(15).

PMID: 39124987 PMC: 11313757. DOI: 10.3390/molecules29153581.

Molecular characterization of SARS-CoV-2 nucleocapsid protein.

Huang Y, Chen J, Chen S, Huang C, Li B, Li J Front Cell Infect Microbiol. 2024; 14:1415885.

PMID: 38846351 PMC: 11153676. DOI: 10.3389/fcimb.2024.1415885.

References

Hayashi T, Yaegashi N, Konishi I . EFFECT OF RBD MUTATIONS IN SPIKE GLYCOPROTEIN OF SARS-COV-2 ON NEUTRALIZING IGG AFFINITY. Georgian Med News. 2023; (340-341):37-46. View

Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S . The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell. 2020; 182(5):1284-1294.e9. PMC: 7366990. DOI: 10.1016/j.cell.2020.07.012. View

Kim J, Jang J, Kim J, Chung Y, Yoo C, Han M . Genome-Wide Identification and Characterization of Point Mutations in the SARS-CoV-2 Genome. Osong Public Health Res Perspect. 2020; 11(3):101-111. PMC: 7282418. DOI: 10.24171/j.phrp.2020.11.3.05. View

Brewster U, Perazella M . The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med. 2004; 116(4):263-72. DOI: 10.1016/j.amjmed.2003.09.034. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Liu D, Fung T, Chong K, Shukla A, Hilgenfeld R . Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res. 2014; 109:97-109. PMC: 7113789. DOI: 10.1016/j.antiviral.2014.06.013. View

Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi J . Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020; 9. PMC: 7723407. DOI: 10.7554/eLife.61312. View

Starr T, Greaney A, Addetia A, Hannon W, Choudhary M, Dingens A . Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021; 371(6531):850-854. PMC: 7963219. DOI: 10.1126/science.abf9302. View

10.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

11.

Plante J, Liu Y, Liu J, Xia H, Johnson B, Lokugamage K . Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2020; 592(7852):116-121. PMC: 8158177. DOI: 10.1038/s41586-020-2895-3. View

12.

Ohtsuka N, Taguchi F . Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype. J Virol. 1997; 71(11):8860-3. PMC: 192354. DOI: 10.1128/JVI.71.11.8860-8863.1997. View

13.

Zhang L, Jackson C, Mou H, Ojha A, Peng H, Quinlan B . SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020; 11(1):6013. PMC: 7693302. DOI: 10.1038/s41467-020-19808-4. View

14.

Sanche S, Lin Y, Xu C, Romero-Severson E, Hengartner N, Ke R . High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020; 26(7):1470-1477. PMC: 7323562. DOI: 10.3201/eid2607.200282. View

15.

Kleine-Weber H, Schroeder S, Kruger N, Prokscha A, Naim H, Muller M . Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. Emerg Microbes Infect. 2020; 9(1):155-168. PMC: 7006675. DOI: 10.1080/22221751.2020.1713705. View

16.

Deng X, Garcia-Knight M, Khalid M, Servellita V, Wang C, Morris M . Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021; 184(13):3426-3437.e8. PMC: 8057738. DOI: 10.1016/j.cell.2021.04.025. View

17.

Pinheiro D, Santos R, Jardim P, Silva E, Reis A, Pedrino G . The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: A genetic association study in Brazilian patients. PLoS One. 2019; 14(8):e0221248. PMC: 6701835. DOI: 10.1371/journal.pone.0221248. View

18.

Suryamohan K, Diwanji D, Stawiski E, Gupta R, Miersch S, Liu J . Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2. Commun Biol. 2021; 4(1):475. PMC: 8041869. DOI: 10.1038/s42003-021-02030-3. View

19.

Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P . Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020; 383(16):1522-1534. PMC: 7315890. DOI: 10.1056/NEJMoa2020283. View

20.

Villoutreix B, Calvez V, Marcelin A, Khatib A . In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface. Int J Mol Sci. 2021; 22(4). PMC: 7915722. DOI: 10.3390/ijms22041695. View